{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "DJ1",
        "Protein_Change": {
          "ref": "E",
          "alt": "D",
          "position": "64"
        },
        "variant_string_id": "DJ1 E64D"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "DJ1 mutations lead to an early onset form of Parkinson's disease, with the E64D mutation causing a reduction in dopamine transporter binding in the striatum.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to dopaminergic system dysfunction, which is relevant to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses PET scans to measure dopamine transporter binding and cell-based assays to evaluate protein stability and localization.",
          "judgment": "Yes",
          "reasoning": "PET scans and cell-based assays are appropriate for modeling dopaminergic system dysfunction and protein mislocalization in Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes controls such as wild-type DJ1 and known pathogenic variants like L166P, with experiments repeated multiple times.",
          "judgment": "Yes",
          "reasoning": "The study uses appropriate controls and replicates, fulfilling the requirements for this step.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study uses known pathogenic variant L166P as a control, which is classified as pathogenic without relying on PS3/BS3.",
          "judgment": "Yes",
          "reasoning": "The use of L166P as a control supports the pathogenic classification of E64D.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_step": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide a direct OddsPath calculation but uses multiple known pathogenic controls.",
          "judgment": "At least 11",
          "reasoning": "The study uses sufficient pathogenic controls to support a moderate strength classification.",
          "next_step_or_outcome": "Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The E64D variant in DJ1 is supported by functional evidence as pathogenic due to its impact on dopamine transporter binding and protein mislocalization, with moderate strength based on the use of multiple pathogenic controls."
    },
    {
      "variant_id": {
        "Gene": "DJ1",
        "Protein_Change": {
          "ref": "L",
          "alt": "P",
          "position": "166"
        },
        "variant_string_id": "DJ1 L166P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "DJ1 mutations lead to early onset Parkinson's disease, with L166P causing significant protein mislocalization and instability.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to protein mislocalization and instability, relevant to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses cell-based assays to evaluate protein stability and localization.",
          "judgment": "Yes",
          "reasoning": "Cell-based assays are appropriate for modeling protein mislocalization and instability in Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes controls such as wild-type DJ1 and repeats experiments multiple times.",
          "judgment": "Yes",
          "reasoning": "The study uses appropriate controls and replicates, fulfilling the requirements for this step.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_step": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study uses known pathogenic variant L166P as a control, which is classified as pathogenic without relying on PS3/BS3.",
          "judgment": "Yes",
          "reasoning": "The use of L166P as a control supports the pathogenic classification of other variants.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_step": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not provide a direct OddsPath calculation but uses multiple known pathogenic controls.",
          "judgment": "At least 11",
          "reasoning": "The study uses sufficient pathogenic controls to support a moderate strength classification.",
          "next_step_or_outcome": "Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The L166P variant in DJ1 is supported by functional evidence as pathogenic due to its impact on protein mislocalization and instability, with moderate strength based on the use of multiple pathogenic controls."
    }
  ]
}
